Medical Oncology
Physician insights on cancer treatment protocols, immunotherapy, targeted therapies, and clinical trial updates.
Recent Discussions
What factors would make you choose IPI3/NIVO1 frontline for advanced unresectable and metastatic HCC based on CheckMate 9DW?
Great question! CheckMate 9DW with the combination IPI3/NIVO1 compared to sorafenib/lenvatinib (85% were lenvatinib in the control arm) significantly improved OS (23.7 months vs 20.6 months, HR 0.79, P-value 0.018), response 36% vs 13% (P-value <0.0001). Based on these data, it received FDA approval...
How does your management of stomatitis from Dato-DXd compare to your approach for stomatitis from other cancer-directed treatments?
By and large, the treatment is similar, though dexamethasone rinses are essential (10 mL oral solution, 4 times a day). Patients should swish/gargle the steroid solution for 1-2 minutes, then spit it out. Food and drink should be avoided for 30 minutes afterward. Similarly, patients should avoid cau...
For patients with newly diagnosed unmutated CLL how will you decide between BTKi alone vs Ven/BTKi vs Ven/Obin vs Ven/Obin/Acalabrutinib?
My usual practice has been Ven Obin for most patients, even unmutated, but if they have bulky nodes and are young/fit, I am now adding acala to that and giving the 3-drug regimen. Continuous BTKi in my practice is mostly reserved for the older or less fit patients, or those who really, really don’t ...
For patients with newly diagnosed unmutated CLL how will you decide between BTKi alone vs Ven/BTKi vs Ven/Obin vs Ven/Obin/Acalabrutinib?
My usual practice has been Ven Obin for most patients, even unmutated, but if they have bulky nodes and are young/fit, I am now adding acala to that and giving the 3-drug regimen. Continuous BTKi in my practice is mostly reserved for the older or less fit patients, or those who really, really don’t ...
How, if at all, are you employing ctDNA in the management of patients with colon cancer?
This is a great question and one that has been a huge point of extensive discussion with a lot of my patients and colleagues. I think there is a lot of variation at this time amongst providers in the implementation of this test, but I will provide my general approach and welcome other approaches as ...
What is your approach to VTE prophylaxis in hospitalized patients who are already on DAPT?
DAPT by itself is not considered DVT prophylaxis in patients at high risk of DVT. However, LMWH at prophylactic doses can increase the need for transfusions in patients on DAPT, without decreasing VTE rates. In general, I consider patients individually: Do they still need DAPT? With discontinuity o...
How do you manage maintenance for BRAF V600E-mutated metastatic colon cancer responding to FOLFOX + encorafenib + cetuximab (BREAKWATER) in the first line?
I would treat with mFOLFOX plus encorafenib and cetuximab for 8-12 cycles, provided responding/tolerating, and then maintain on encorafenib and cetuximab without the 5-FU till progression/intolerance.
Do you routinely check serum phosphorus levels after IV iron therapy?
Only before and after FCM. I hold subsequent doses if phosphorus low. There is no need to monitor with the other formulations. For people needing multiple doses of IV iron (IBD, bariatric surgery, heavy uterine bleeding, angiodysplasia), I avoid FCM.
Do you recommend vitamin C supplementation with PO iron in patients with iron deficiency?
Vitamin C supplementation is unnecessary. Taking the iron with a glass of orange juice away from food and especially coffee optimizes absorption. That being said vitamin C does no harm. See vonSiebenthal et al eClinical Works 2023 (Lancet publication), Benson et al, Lancet Haem 2025 or Auerbach et a...
When would you use AVD + brentuximab instead of ABVD for newly diagnosed stage 3 or 4 Hodgkin lymphoma?
By reducing the risk of primary treatment failure from 23% to 18%, the ECHELON-1 study demonstrated that compared to ABVD, AVD + brentuximab vedotin reduces the risk of primary treatment failure by about 25% for patients with advanced-stage classic Hodgkin lymphoma. If given with prophylactic G-CSF,...